Arbutus Biopharma (ABUS) Common Equity (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Common Equity for 17 consecutive years, with $260.2 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity rose 228.68% year-over-year to $260.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $260.2 million (up 228.68% YoY) and the FY2025 annual result came in at $76.6 million, down 21.35% from the prior year.
• Common Equity advanced to $260.2 million in Q1 2026 per ABUS's latest filing, from $76.6 million in the prior quarter.
• Over the last five years, Common Equity for ABUS reached as high as $260.2 million in Q1 2026 and fell as low as $76.6 million in Q4 2025.
• A 5-year average of $124.9 million and a median of $119.3 million in 2023 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity tumbled 32.24% — and 2026, when it jumped 228.68%.
• Year by year, Common Equity stood at $136.9 million in 2022, then fell by 22.53% to $106.0 million in 2023, then declined by 8.16% to $97.4 million in 2024, then decreased by 21.35% to $76.6 million in 2025, then surged by 239.76% to $260.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $260.2 million, $76.6 million, and $77.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.